Polyreactivity and autoreactivity among HIV-1 antibodies

Journal of Virology

Volumn 89, Issue 1, 2015, Pages 784-798

  Liu, Mengfei ^a,b   Yang, Guang ^a   Wiehe, Kevin ^a   Nicely, Nathan I ^a   Vandergrift, Nathan A ^a   Rountree, Wes ^a   Bonsignori, Mattia ^a   Munir Alam, S ^a   Gao, Jingyun ^a,c   Haynes, Barton F ^a   Kelsoe, Garnett ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAINE HOMOCYSTEINE METHYLTRANSFERASE; BETAINE HOMOCYSTEINE METHYLTRANSFERASE 2; CD4 ANTIBODY; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INFLIXIMAB; NEUTRALIZING ANTIBODY; PALIVIZUMAB; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; AUTOANTIBODY; PROTEIN BINDING;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; AUTOREACTIVITY; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOREGULATION; MOLECULAR MIMICRY; OPEN READING FRAME; POLYREACTIVITY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MICROARRAY; QUANTITATIVE ANALYSIS; SEQUENCE ALIGNMENT; VIRUS NEUTRALIZATION; IMMUNOLOGY; MICROARRAY ANALYSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AUTOANTIBODIES; HIV ANTIBODIES; HIV-1; HUMANS; MICROARRAY ANALYSIS; PROTEIN ARRAY ANALYSIS; PROTEIN BINDING;

EID: 84919430580     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02378-14     Document Type: Article

References (65)

1. Mascola JR, Haynes BF. 2013. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 254:225-244. http://dx.doi.org/10.1111/imr.12075.
2. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L. 2011. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 85:4828-4840. http://dx.doi.org/10.1128/JVI.00198-11.
3. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 7:e1001251. http://dx.doi.org/10.1371/journal.ppat.1001251.
4. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
5. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. http://dx.doi.org/10.1126/science.1187659.
6. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Olivera TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton D, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637. http://dx.doi.org/10.1126/science.1207227.
7. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, Zhu J, Shapiro L, Mullikin JC, Gnanakaran S, Hraber P, Wiehe K, Kelsoe G, Yang G, Xia SM, Montefiori DC, Parks R, Lloyd KE, Scearce RM, Soderberg KA, Cohen M, Kamanga G, Louder MK, Tran LM, Chen Y, Cai F, Chen S, Moquin S, Du X, Joyce MG, Srivatsan S, Zhang B, Zheng A, Shaw GM, Hahn BH, Kepler TB, Korber BT, Kwong PD, Mascola JR, Haynes BF. 2013. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496: 469-476. http://dx.doi.org/10.1038/nature12053.
8. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, Palese P, Katinger H. 1994. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 68:4031-4034.
9. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17:1757-1765. http://dx.doi.org/10.1089/08892220152741450.
10. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406-412. http://dx.doi.org/10.1038/nature11544.
11. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, Haynes BF. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85:9998-10009. http://dx.doi.org/10.1128/JVI.05045-11.
12. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100-1108.
13. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. http://dx.doi.org/10.1038/nature01470.
14. Binley JM, Ban YEA, Crooks ET, Eggink D, Osawa K, Schief WR, Sanders RW. 2010. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 84:5637-5655. http://dx.doi.org/10.1128/JVI.00105-10.
15. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678-682. http://dx.doi.org/10.1038/nature01188.
16. Zhu P, Liu J, Bess J, Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852. http://dx.doi.org/10.1038/nature04817.
17. Haynes BF, Fleming J, St. Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908. http://dx.doi.org/10.1126/science.1111781.
18. Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, Kepler TB, Alam SM, Liao HX, Cain DW, Spicer L, Vandeberg JL, Haynes BF, Kelsoe G. 2013. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 210:241-256. http://dx.doi.org/10.1084/jem.20121977.
19. Verkoczy L, Diaz M, Holl TM, Ouyang YB, Bouton-Verville H, Alam SM, Liao HX, Kelsoe G, Haynes BF. 2010. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA 107:181-186. http://dx.doi.org/10.1073/pnas.0912914107.
20. Verkoczy L, Chen Y, Bouton-Verville H, Zhang J, Diaz M, Hutchinson J, Ouyang YB, Alam SM, Holl TM, Hwang KK, Kelsoe G, Haynes BF. 2011. Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH × VL knockin mice reveals multiple tolerance controls. J Immunol 187:3785-3797. http://dx.doi.org/10.4049/jimmunol.1101633.
21. Chen Y, Zhang J, Hwang KK, Bouton-Verville H, Xia SM, Newman A, Ouyang YB, Haynes BF, Verkoczy L. 2013. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J Immunol 191:1260-1275. http://dx.doi.org/10.4049/jimmunol.1300770.
22. Bonsignori M, Wiehe K, Grimm SK, Lynch R, Yang G, Kozink DM, Perrin F, Cooper AJ, Hwang KK, Chen X, Liu M, McKee K, Parks RJ, Eudailey J, Wang M, Clowse M, Criscione-Schreiber LG, Moody MA, Ackerman ME, Boyd SD, Gao F, Kelsoe G, Verkoczy L, Tomaras GD, Liao HX, Kepler TB, Montefiori DC, Mascola JR, Haynes BF. 2014. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest 124:1835-1843. http://dx.doi.org/10.1172/JCI73441.
23. Mouquet H, Warncke M, Scheid JF, Seaman MS, Nussenzweig MC. 2012. Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci USA 109:875-880. http://dx.doi.org/10.1073/pnas.1120059109.
24. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. 2003. Predominant autoantibody production by early human B cell precursors. Science 301:1374-1377. http://dx.doi.org/10.1126/science.1086907.
25. Kwong PD, Mascola JR. 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37:412-425. http://dx.doi.org/10.1016/j.immuni.2012.08.012.
26. Mouquet H, Nussenzweig MC. 2012. Polyreactive antibodies in adaptive immune responses to viruses. Cell Mol Life Sci 69:1435-1445. http://dx.doi.org/10.1007/s00018-011-0872-6.
27. Scherer EM, Zwick MB, Teyton L, Burton DR. 2007. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21:2131-2139. http://dx.doi.org/10.1097/QAD.0b013e3282a4a632.
28. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, Walker BD, Ho DD, Wilson PC, Seaman MS, Eisen HN, Chakraborty AK, Hope TJ, Ravetch JV, Wardemann H, Nussenzweig MC. 2010. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467: 591-595. http://dx.doi.org/10.1038/nature09385.
29. Verkoczy L, Chen Y, Zhang J, Bouton-Verville H, Newman A, Lockwood B, Scearce RM, Montefiori DC, Dennison SM, Xia SM, Hwang KK, Liao HX, Alam SM, Haynes BF. 2013. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. J Immunol 191:2538-2550. http://dx.doi.org/10.4049/jimmunol.1300971.
30. Ma BJ, Alam SM, Go EP, Lu X, Desaire H, Tomaras GD, Bowman C, Sutherland LL, Scearce RM, Santra S, Letvin NL, Kepler TB, Liao HX, Haynes BF. 2011. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog 7:e1002200. http://dx.doi.org/10.1371/journal.ppat.1002200.
31. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110. http://dx.doi.org/10.1016/S0140-6736(94)90628-9.
32. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, Givner LB, Jennings TL, Top FH, Jr, Carlin D, Connor E. 1998. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 17:110-115. http://dx.doi.org/10.1097/00006454-199802000-00006.
33. Ronchi VP, Klein JM, Haas AL. 2013. E6AP/UBE3A ubiquitin ligase harbors two E2-ubiquitin binding sites. J Biol Chem 288:10349-10360. http://dx.doi.org/10.1074/jbc.M113.458059.
34. Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. 2010. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci USA 107:19985-19990. http://dx.doi.org/10.1073/pnas.1014074107.
35. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, Pollara J, Rao M, Peachman KK, Santra S, Letvin NL, Karasavvas N, Yang ZY, Dai K, Pancera M, Gorman J, Wiehe K, Nicely NI, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Sinangil F, Kim JH, Michael NL, Kepler TB, Kwong PD, Mascola JR, Nabel GJ, Pinter A, Zolla-Pazner S, Haynes BF. 2013. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38:176-186. http://dx.doi.org/10.1016/j.immuni.2012.11.011.
36. Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu X, Zhu J, Boyington JC, Chen X, Shi W, Yang ZY, Doria-Rose NA, McKee K, O'Dell S, Schmidt SD, Chuang GY, Druz A, Soto C, Yang Y, Zhang B, Zhou T, Todd JP, Lloyd KE, Eudailey J, Roberts KE, Donald BR, Bailer RT, Ledgerwood J, Mullikin JC, Shapiro L, Koup RA, Graham BS, Nason MC, Connors M, Haynes BF, Rao SS, Roederer M, Kwong PD, Mascola JR, Nabel GJ. 2014. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 88:12669-12682. http://dx.doi.org/10.1128/JVI.02213-14.
37. Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H, Gnanapragasam PNP, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334:1289-1293. http://dx.doi.org/10.1126/science.1213782.
38. Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR. 2008. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virology 381:251-260. http://dx.doi.org/10.1016/j.virol.2008.08.032.
39. Winkler TH, Jahn S, Kalden JR. 1991. IgG human monoclonal anti-DNA autoantibodies from patients with systemic lupus erythematosus. Clin Exp Immunol 85:379-385.
40. Schwarz SE, Rosa JL, Scheffner M. 1998. Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7. J Biol Chem 273:12148-12154. http://dx.doi.org/10.1074/jbc.273.20.12148.
41. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817. http://dx.doi.org/10.1126/science.1192819.
42. Huang L, Kinnucan E, Wang G, Beaudenon S, Howley PM, Huibregtse JM, Pavletich NP. 1999. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science 286:1321-1326. http://dx.doi.org/10.1126/science.286.5443.1321.
43. Ditzel HJ, Itoh K, Burton DR. 1996. Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection. J Immunol 157:739-749.
44. Satoh M, Kuroda Y, Yoshida H, Behney KM, Mizutani A, Akaogi J, Nacionales DC, Lorenson TD, Rosenbauer RJ, Reeves WH. 2003. Induction of lupus autoantibodies by adjuvants. J Autoimmun 21:1-9. http://dx.doi.org/10.1016/S0896-8411(03)00083-0.
45. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, Xia SM, Rits-Volloch S, Sun L, Harrison SC, Haynes BF, Chen B. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 106:20234-20239. http://dx.doi.org/10.1073/pnas.0908713106.
46. Doyle-Cooper C, Hudson KE, Cooper AB, Ota T, Skog P, Dawson PE, Zwick MB, Schief WR, Burton DR, Nemazee D. 2013. Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J Immunol 191:3186-3191. http://dx.doi.org/10.4049/jimmunol.1301285.
47. Kouskoff V, Lacaud G, Nemazee D. 2000. T cell-independent rescue of B lymphocytes from peripheral immune tolerance. Science 287:2501-2503. http://dx.doi.org/10.1126/science.287.5462.2501.
48. Ota T, Doyle-Cooper C, Cooper AB, Doores KJ, Aoki-Ota M, Le K, Schief WR, Wyatt RT, Burton DR, Nemazee D. 2013. B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates. J Immunol 191:3179-3185. http://dx.doi.org/10.4049/jimmunol.1301283.
49. Gustin RM, Bichell TJ, Bubser M, Daily J, Filonova I, Mrelashvili D, Deutch AY, Colbran RJ, Weeber EJ, Haas KF. 2010. Tissue-specific variation of Ube3a protein expression in rodents and in a mouse model of Angelman syndrome. Neurobiol Dis 39:283-291. http://dx.doi.org/10.1016/j.nbd.2010.04.012.
50. Saito Y, Hayaishi O, Rothberg S. 1957. Studies on oxygenases: enzymatic formation of 3-hydroxy-L-kynurenine from L-kynurenine. J Biol Chem 229:921-934.
51. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. 2014. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 42:D199-D205. http://dx.doi.org/10.1093/nar/gkt1076.
52. Moffett JR, Namboodiri MA. 2003. Tryptophan and the immune response. Immunol Cell Biol 81:247-265. http://dx.doi.org/10.1046/j.1440-1711.2003.t01-1-01177.x.
53. Smith AJ, Stone TW, Smith RA. 2007. Neurotoxicity of tryptophan metabolites. Biochem Soc Trans 35:1287-1289. http://dx.doi.org/10.1042/BST0351287.
54. Kishino T, Lalande M, Wagstaff J. 1997. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 15:70-73. http://dx.doi.org/10.1038/ng0197-70.
55. Achim CL, Heyes MP, Wiley CA. 1993. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest 91:2769-2775. http://dx.doi.org/10.1172/JCI116518.
56. Bowes T, Wagner ER, Boffey J, Nicholl D, Cochrane L, Benboubetra M, Conner J, Furukawa K, Furukawa K, Willison HJ. 2002. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barre syndrome. Infect Immun 70:5008-5018. http://dx.doi.org/10.1128/IAI.70.9.5008-5018.2002.
57. Oldstone MBA. 1998. Molecular mimicry and immune-mediated diseases. FASEB J 12:1255-1265.
58. Moore PL, Gray ES, Morris L. 2009. Specificity of the autologous neutralizing antibody response. Curr Opin HIV AIDS 4:358-363. http://dx.doi.org/10.1097/COH.0b013e32832ea7e8.
59. Mascola JR, Montefiori DC. 2010. The role of antibodies in HIV vaccines. Annu Rev Immunol 28:413-444. http://dx.doi.org/10.1146/annurev-immunol-030409-101256.
60. Holl TM, Yang G, Kuraoka M, Verkoczy L, Alam SM, Moody MA, Haynes BF, Kelsoe G. 2014. Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes. J Immunol 192:3269-3279. http://dx.doi.org/10.4049/jimmunol.1302829.
61. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 30:423-433. http://dx.doi.org/10.1038/nbt.2197.
62. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. 2007. Autoreactivity in human IgG+ memory B cells. Immunity 26:205-213. http://dx.doi.org/10.1016/j.immuni.2007.01.009.
63. Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD. 2011. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol Med 17:108-116. http://dx.doi.org/10.1016/j.molmed.2010.10.008.
64. Nakamura KJ, Cerini C, Sobrera ER, Heath L, Sinkala M, Kankasa C, Thea DM, Mullins JI, Kuhn L, Aldrovandi GM. 2013. Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies. AIDS 27:337-346. http://dx.doi.org/10.1097/QAD.0b013e32835cadd6.
65. Sigounas G, Harindranath N, Donadel G, Notkins AL. 1994. Half-life of polyreactive antibodies. J Clin Immunol 14:134-140. http://dx.doi.org/10.1007/BF01541346.